Skip to Content

Guardant Health Inc GH Stock Quote

| Rating as of

Morningstar‘s Stock Analysis GH

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Guardant's Liquid Biopsy Pipeline May Pay Off Soon

Aaron Degagne, CFA Equity Analyst

Business Strategy and Outlook

| Julie Utterback, CFA |

Guardant Health is taking a slightly different approach than liquid biopsy peers Illumina and Exact Sciences by initially targeting the early-stage detection and screening niche through individualized cancer tests. We expect Guardant will be a first mover in colorectal cancer liquid biopsy with the Lunar-2 test likely to be one of the first to obtain Food and Drug Administration approval, and we estimate the U.S. market opportunity at $18 billion for colorectal cancer screening alone, the initial focus of the test. We believe Guardant is ahead of peers in single-cancer screening, with the firm currently enrolling 10,000 people for its Eclipse clinical trial, which could lead to FDA approval within the next year or so if the full trial supports initial promising data. If this occurs, we would expect the company to rapidly pursue other indications, such as lung, breast, and ovarian cancer, and a possible combination multi-cancer test in the long run.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics GH

Company Profile GH

Business Description

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.

505 Penobscot Drive
Redwood City, CA, 94063
T +1 855 698-8887
Industry Diagnostics & Research
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 1,373